Fast acting insulin lispro for the treatment of diabetes mellitus
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Ultra-rapid acting insulin lispro (Lyumjev®▼, Lilly) is a new formulation of insulin lispro with added treprostinil and citrate to produce a more rapid onset of action. It is the second ultra-rapid acting insulin analogue to be launched after Fiasp®▼.
Download the full review below to read more.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation
Cardiovascular outcomes associated with SGLT2 inhibitors (update 2)
Overview
Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.
The sodium-glucose co-transporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population at increased risk of cardiovascular events. Recent clinical trials and cohort studies have assessed whether the SGLT2 inhibitors reduce this risk.
Download the full review below to read more.
Cardiovascular outcomes associated with GLP1 receptor agonists (updated)
Overview
Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.
The glucagon-like peptide 1 receptor agonists (GLP1RAs) dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population which is also at increased risk of cardiovascular events. Good quality evidence assessed the effect of these drugs on cardiovascular outcomes.
Download the full review below to read more.
Flash glucose monitoring prescribing update – Freestyle Libre
Prescribing for Population Health (PPH) is an ongoing series that aims to support ICSs to improve the health of the populations they serve. PPHs use prescribing data, biomedical literature and other data sources to provide new insights.
This publication highlights the variation in flash glucose monitoring prescribing, specifically Freestyle Libre, in people with Type 1 diabetes mellitus (T1DM). Prescribing is considered both in terms of the percentage of unique people prescribed this type of monitoring system and also the prescribing volume in 19/20 relative to the NHS England (NHSE) National funding arrangements.
Estimated avoidance of hospital admissions attributable to FL prescribing has also been quantified in terms of frequency and cost, and reduction in blood glucose test strips has been estimated.
There are three versions of this publication; please select the appropriate version for your region below.
Oral semaglutide for the treatment of type 2 diabetes mellitus
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Semaglutide (Rybelsus®▼) is the first oral GLP1 receptor agonist (GLP1RA), for the treatment of adults with type 2 diabetes mellitus.
Download the full review below to read more.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation
Comparison of GLP 1 Agonists (update November 2020)
Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area.
Several glucagon-like peptide receptor 1 agonists are marketed, with differences in licensing, formulation, and administration. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.
Comparison of SGLT2 inhibitors (update)
Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area.
Several sodium-glucose co-transporter 2 inhibitors are marketed. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.
Insulin glargine plus lixisenatide (Suliqua) for the treatment of T2DM
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Suliqua®▼ (Sanofi) is a fixed ratio combination of insulin glargine and lixisenatide licensed for the treatment of adults with type 2 diabetes mellitus.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
Download the full review below to read more.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation
Ertugliflozin for type 2 diabetes
Overview
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Ertugliflozin is the fourth sodium glucose co-transporter-2 inhibitor to be licensed in the UK. It is indicated as an adjunct to diet and exercise control to improve glycaemic control in adults with type 2 diabetes.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation